Oxford Nanopore and bioMérieux SA have announced a substantial $93 million investment by bioMérieux in Oxford Nanopore.
Furthermore, bioMérieux anticipates periodic market acquisitions of Oxford Nanopore's shares, potentially up to an additional 3.5% of the company's shares, contingent upon availability and pricing.
This financial infusion solidifies the partnership between the two entities, aligning with Oxford Nanopore's strategic focus on clinical markets as outlined in the April announcement. The funding will bolster the development of products within Oxford Nanopore's portfolio tailored for In Vitro Diagnostics (IVD) markets, synergizing with bioMérieux's commitment to advancing global public health.
Through this collaboration and financial commitment, the two companies plan to leverage Oxford Nanopore's pioneering nanopore-based IVD solution alongside bioMérieux's proficiency in IVD across Research and Development, Regulatory Affairs, Medical Affairs, and Market Access. As part of this agreement, an IVD Advisory Board will be established to facilitate the integration of nanopore technology into routine clinical practice.
Nanopore-based sequencing represents an innovative approach enabling the analysis of lengthy DNA or RNA fragments. This operates by monitoring alterations in an electrical current as nucleic acids pass through a protein nanopore. The resulting signal is deciphered to yield the specific DNA or RNA sequence. The distinctive real-time, scalable attributes, coupled with advancements in single-nucleotide sequencing accuracy, position this technology as exceptionally suited for the swift and cost-effective characterization of pathogens in clinical samples.
Together, the companies are addressing a substantial unmet requirement within the clinical and diagnostic sectors—a space where nanopore sequencing uniquely excels in providing information-rich, rapid, accessible, and economically viable sequencing solutions.
Oxford Nanopore reiterates its commitment to achieving adjusted EBITDA breakeven by the close of 2026.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special
offers from Pharmaceutical Outsourcing – all delivered right to your inbox! Sign up now!